Surgery

Global Skull Clamp Market Analysis Report 2023-2024 & 2029 | Now Available - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Health, Surgery, Neurology, Medical Devices, MRI, Prevalence, OPT, Application, Incidence, COVID-19, Acquisition, DSM-IV codes, Safety, Neurosurgery, Ageing, Video game

The "Global Skull Clamp Market: Analysis By Product, By Application, By Material, By Accessories, By End User, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Skull Clamp Market: Analysis By Product, By Application, By Material, By Accessories, By End User, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global skull clamp market value stood at US$2.21 billion in 2023 and is expected to reach US$3.79 billion by 2029.
  • The global skull clamp market has witnessed continuous growth attributed to several key factors.
  • The global skull clamp market is fragmented, with an increasing number of large and medium-sized players accounting for the majority of the market revenue, and the presence of a substantial number of regional market players with limited business offerings and customer base.

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

Retrieved on: 
Friday, March 22, 2024
Research, Other Health, General Health, Oncology, Medical Devices, Genetics, Health Technology, Surgery, Clinical Trials, Science, Biotechnology, Health, Other Science, Online, Sentinel lymph node, Survival, Risk, Annual general meeting, Patient, Neoplasm, Society, Lymph, Abstract, SSO, Lymph node, Melanoma, Trial of the century, Recurrence, Metastasis, SLN, Medical imaging

“We have also demonstrated that our test is a strong and independent predictor of metastasis.

Key Points: 
  • “We have also demonstrated that our test is a strong and independent predictor of metastasis.
  • The study that was orally presented at SSO 2024 demonstrates that patients who did avoid an SLNB procedure had excellent outcomes to date.
  • Additionally, at three years, all patients with a low-risk DecisionDx-Melanoma test result were recurrence free (recurrence free survival of 100%).
  • These data demonstrate that use of DecisionDx-Melanoma test results can guide accurate, risk-aligned clinical decision-making regarding the SLNB surgical procedure, within current guidelines.

Dr. Mark Silver Offers Options to Avoid Back Surgery

Retrieved on: 
Friday, March 22, 2024
General Health, Health, Surgery, Neurology, Nervous system, Nerve, Pain, Patient, Neurosurgery, Brain, Spinal cord stimulator, Diabetic neuropathy, Back pain, Dentistry

Dr. Mark Silver , founder of the Silver Spine and Neurological Center , offers treatments that can help many patients avoid the need for surgery to address back pain.

Key Points: 
  • Dr. Mark Silver , founder of the Silver Spine and Neurological Center , offers treatments that can help many patients avoid the need for surgery to address back pain.
  • “Surgery can be an effective form of back pain management,” said Dr. Mark Silver.
  • “But there are many other treatments that can avoid the need for surgery and should be considered.”
    Dr. Mark Silver is an expert on Neuromodulation, techniques that act directly on the nervous system.
  • By changing the way a patient’s nerves carry information to and from the brain, pain can be decreased and mobility improved.

Global Balloon Catheter Market Analysis Report 2023-2030: Minimally Invasive Solutions and Age-Associated Cardiovascular Problems Drive Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, Coronary artery disease, Balloon catheter, Neurology, Prevalence, Headache, Urbanization, Blood, Peripheral artery disease, Urology, Angioplasty, Nylon, Hospital, Restenosis, Research, Splenic infarction, Telehealth, Heart, Stroke, Artery, Safety, Prognosis, Catheter, FDA, Artificial intelligence, CAD, Ageing, Medical device

The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of age-associated cardiovascular problems propels balloon catheter demand, significantly increasing the medical device market and enhancing the care of growing older populations globally.
  • Offering minimally invasive alternatives to conventional surgeries, balloon catheters lead to faster recuperation instances, decreased dangers, and progressed patient effects, driving market increase towards minimally invasive tactics.
  • By product type, the Global Balloon Catheter Market is divided into Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, Scoring Balloon Catheter, Stent Graft Balloon Catheter, and Others.

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Retrieved on: 
Friday, March 22, 2024
Software, Radiology, Surgery, General Health, Health, Artificial Intelligence, Medical Devices, Technology, PAE, Interventional radiology, Automation, 2D, ASSIST, Vascular disease, Drainage, Prostatic artery embolization, Allia, OEC, Patient, Artificial intelligence, Society of Interventional Radiology, 3D, Prostate, AI, Quality of life, Artery, Woman, Workflow, GE HealthCare, 3D CT, Embo, E10, Injection, Therapy, BPH, SIR, Medical imaging

GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.
  • The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions.
  • As GE HealthCare continues to advance the Allia IGS platform and interventional innovation, Embo ASSIST AI is the latest addition to the company's ASSIST imaging software.
  • “Interventional CT: CT guidance assisted by electromagnetic navigation for percutaneous interventions” with Dr. Francois Cornelis10 on Monday, March 25 from 2:30 - 3:00pm.

Sage Dental Acquires Tampa-Based Pediatrics Dental Office

Retrieved on: 
Thursday, March 21, 2024
General Health, Health, Surgery, Dental, Dental care, Dentistry, Growth, DDS, Patient, Orthodontics, Education, Acquisition, DSO, Pediatrics

As part of the DSO’s ongoing strategy to expand its service offerings for patients, the acquisition marks its first location dedicated specifically to pediatrics and orthodontics, with expectations to open additional Sage Dental Kids facilities.

Key Points: 
  • As part of the DSO’s ongoing strategy to expand its service offerings for patients, the acquisition marks its first location dedicated specifically to pediatrics and orthodontics, with expectations to open additional Sage Dental Kids facilities.
  • Stepanski and his team have built a tremendous connection with their community and we’re proud they have chosen Sage Dental to further their legacy,” said Thomas Marler, CEO of Sage Dental.
  • We're excited to bring our innovative pediatric model to more communities with the expansion of our Sage Dental Kids practices."
  • Sage Dental has served more than 1 million patients since 2020 – and many Sage Dental patients currently have children seeking dental care services.

LivaNova to Announce First-Quarter 2024 Results

Retrieved on: 
Thursday, March 21, 2024
Research, General Health, Mental Health, Medical Devices, Hospitals, Health Technology, Surgery, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, PLC, Telephone, LIVN, LivaNova

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time).

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time).
  • The Company will release its first-quarter 2024 results prior to the call.
  • Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast.
  • A replay will be available on the LivaNova website for 90 days following the call.

Medical Second Opinion Market Analysis Report 2024 Featuring Medisense Healthcare, Second Opinion International, Elite Medical Services, Cigna, and Helsana - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 21, 2024
Technology, Surgery, Men, Managed Care, Professional Services, Hospitals, Consumer, Health, Health Technology, Health Insurance, Other Technology, Telemedicine, Virtual Medicine, Other Consumer, Insurance, Women, Practice Management, Oncology, Online, Diagnosis, Incidence, Hospital, Investment, M&A, Growth, Porter's five forces analysis, Medical device

The "Medical Second Opinion Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Second Opinion Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The future of the global medical second opinion market looks promising with opportunities in the hospitals, online medical second opinion, and health insurance markets.
  • Segmentation Analysis: Medical second opinion market size by disorder type, end use, and region in terms of value ($B).
  • Growth Opportunities: Analysis of growth opportunities in different disorder types, end uses, and regions for the medical second opinion market.

eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient

Retrieved on: 
Thursday, March 21, 2024
Research, Other Health, General Health, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Pelvic floor dysfunction, MGH, Kidney disease, Gene, Organization, Survival, Massachusetts General Hospital, Transplant, Inflammation, Immunosuppression, Kidney failure, Mortality, Coagulation, Hope, Doctor of Philosophy, Expanded access, Quality of life, Genome, Transgene, Hospital, Kidney, Dialysis, CD40L, Courage, Kidney transplantation, Medicine, Dentistry

eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

Key Points: 
  • eGenesis , a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
  • Following the procedure, the patient is in good condition and recovering well at MGH.
  • Yet the demand for organs far outpaces supply, with more than 90,000 individuals on the kidney waitlist and approximately 25,000 kidney transplants performed each year.
  • Decades of progress in cross-species transplantation, accelerated by the advancement of modern genome editing tools and next-generation sequencing, have enabled eGenesis to progress genetically engineered organs to the clinical setting.

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook

Retrieved on: 
Thursday, March 21, 2024
Medical Devices, Health, Surgery, Health Technology, General Health, Biotechnology, Webcast, OEM, Growth, Advanced Energy

OEM segment revenue increased $0.5 million, or 22% year-over-year, to $2.5 million, compared to $2.1 million in the prior year period.

Key Points: 
  • OEM segment revenue increased $0.5 million, or 22% year-over-year, to $2.5 million, compared to $2.1 million in the prior year period.
  • Domestic revenue increased $2.0 million, or 23% year-over-year, to $10.7 million, and international revenue increased $0.1 million, or 2% year-over-year, to $4.0 million.
  • Gross profit for the three months ended December 31, 2023, increased $0.7 million, or 8% year-over-year, to $8.9 million, compared to $8.2 million in the prior year period.
  • Gross profit margin for the three months ended December 31, 2023, was 60.9%, compared to 65.3% in the prior year period.